20 Results

People

  1. Usmani
    Usmani
  2. Hashmi
    Hashmi
  3. Lesokhin
    Lesokhin
  4. Landau
    Landau
  5. Mailankody
    Mailankody
  6. Perales
    Perales
  7. Rajeeve
    Rajeeve
  8. Shah
    Shah
  9. Shah
    Shah
  10. Brumwell
    Brumwell

Groups

  1. Department of Medicine (8)
  2. Hematologic Malignancies, Division of (8)
  3. Center for Hematologic Malignancies (7)
  4. Bone Marrow Transplant (5)
  5. Hematologic Malignancies Research (4)
  6. Myeloma (3)
  7. Survivorship Research (3)
  8. CTCR Scholars (2)
  9. GME, Medicine (2)
  10. Graduate Medical Education (2)
  1. "ciltacabtagene autoleucel"
Formats
  1. Journal Article (11)
  2. Review (5)
  3. Editorial (2)
  4. Meeting Abstract (1)
  5. Research Letter (1)
Groups
  1. Department of Medicine (8)
  2. Hematologic Malignancies, Division of (8)
  3. Center for Hematologic Malignancies (7)
  4. Bone Marrow Transplant (5)
  5. Hematologic Malignancies Research (4)
  6. Myeloma (3)

More Groups

People
  1. Saad Usmani (5)
  2. Hamza Hashmi (4)
  3. Alexander Lesokhin (3)
  4. Gunjan Shah (2)
  5. Heather Landau (2)
  6. Miguel-Angel Perales (2)

More People

Years
  1. 2025 (2)
  2. 2024 (11)
  3. 2023 (4)
  4. 2022 (2)
  5. 2021 (1)
Publications
  1. Blood (2)
  2. Blood Cancer Journal (2)
  3. Clinical Lymphoma, Myeloma and Leukemia (2)
  4. Frontiers in Oncology (2)
  5. The Lancet Haematology (2)
  6. American Journal of Hematology (1)

More Publications

Publishers
  1. Elsevier Inc. (3)
  2. Frontiers Media S.A. (3)
  3. Nature Publishing Group (3)
  4. American Society of Hematology (2)
  5. Elsevier Science, Inc. (2)
  6. Springer (2)

More Publishers

Results (20)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neurotoxicity and rare adverse events in BCMA-Directed CAR t cell therapy: A comprehensive analysis of real-world FAERS data
    Journal Article

    Ellithi, M.; Elsallab, M.; Lunning, M. A.; Holstein, S. A.; Sharma, S.; Trinh, J. Q.; Ma, J.; Maus, M. V.; Frigault, M. J.; D'Angelo, C. R.
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): Results from a randomised, open-label, phase 3 trial
    Journal Article

    Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L.; Isufi, I.; Harrison, S. J.; Shah, U. A.; more...
    The Lancet Haematology (2025)

    Fulltext@MSK | Save
  • Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
    Journal Article

    Merz, M.; Dima, D.; Hashmi, H.; Ahmed, N.; Stölzel, F.; Holderried, T. A. W.; Fenk, R.; Müller, F.; Tovar, N.; Oliver-Cáldes, A.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis
    Journal Article

    Goel, U.; Dima, D.; Davis, J.; Ahmed, N.; Shaikh, H.; Lochner, J.; Abdallah, A. O.; Khouri, J.; Hashmi, H.; Anwer, F.
    European Journal of Haematology (2024)

    Fulltext@MSK | Save
  • A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
    Review

    Cordas dos Santos, D. M.; Tix, T.; Shouval, R.; Gafter-Gvili, A.; Alberge, J. B.; Cliff, E. R. S.; Theurich, S.; von Bergwelt-Baildon, M.; Ghobrial, I. M.; Subklewe, M.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4
    Journal Article

    Hansen, D. K.; Lu, X.; Puglianini, O. C.; Sorensen, S.; Usmani, S. Z.; Zhang, E.; Huo, S.; Zhang, Y.; Qureshi, Z. P.; Jagannath, S.
    Frontiers in Immunology (2024)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR) T-cell therapy use in patients with multiple myeloma and kidney failure on maintenance hemodialysis: A report of 2 cases
    Journal Article

    Pak, W. L. W.; Brumwell, N. A.; Kabel, C. C.; Gutgarts, V.; Jaffer Sathick, I.; Mailankody, S.; Lesokhin, A. M.; Landau, H. J.; Shaikh, A.
    Kidney Medicine (2024)

    Fulltext@MSK | Save
  • Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma
    Journal Article

    Firestone, R. S.; Socci, N. D.; Shekarkhand, T.; Zhu, M.; Qin, W. G.; Hultcrantz, M.; Mailankody, S.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy
    Journal Article

    Dima, D.; Abdallah, A. O.; Davis, J. A.; Awada, H.; Goel, U.; Rashid, A.; DeJarnette, S.; Anwer, F.; Shune, L.; Raza, S.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Second primary malignancies after commercial CAR T-cell therapy: Analysis of the FDA Adverse Events Reporting System
    Research Letter

    Elsallab, M.; Ellithi, M.; Lunning, M. A.; D'Angelo, C.; Ma, J.; Perales, M. A.; Frigault, M.; Maus, M. V.
    Blood (2024)

    Fulltext@MSK | Save